Cathie Wood is one of the most influential investors in the area of high tech, and her Ark Innovation ETF has been a top performer this year. One of the stocks that Wood has been buying aggressively recently is Verve Therapeutics (NASDAQ: VERV), a company developing base-edited therapies for cardiovascular diseases. The company's base-editing platform is based on tech licensed from Beam Therapeutics.

Verve Therapeutics is a pioneer in the field of in vivo base editing, a technique that allows genes to be modified inside the body. The company's lead product candidate, VERVE-101, is designed to permanently lower LDL cholesterol (the "bad" cholesterol) in patients with heterozygous familial hypercholesterolemia (HeFH), a genetic disorder that causes high cholesterol levels and increases the risk of heart attacks and strokes. 

Image source: Getty Images.

Continue reading

Source Fool.com